Trade Gilead Sciences Inc - GILD CFD
Add to favourite- Summary
- Historical Data
| Spread | 1.51 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 104.69 |
| Open | 103.65 |
| 1-Year Change | 54.06% |
| Day's Range | 103.5 - 105.53 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 103.50 | -0.97 | -0.93% | 104.47 | 105.69 | 103.47 |
| Apr 16, 2025 | 103.65 | -1.56 | -1.48% | 105.21 | 106.34 | 103.65 |
| Apr 15, 2025 | 105.75 | 0.00 | 0.00% | 105.75 | 106.38 | 104.04 |
| Apr 14, 2025 | 105.70 | 2.92 | 2.84% | 102.78 | 107.10 | 102.63 |
| Apr 11, 2025 | 102.95 | 2.04 | 2.02% | 100.91 | 104.74 | 99.71 |
| Apr 10, 2025 | 100.95 | -4.00 | -3.81% | 104.95 | 106.45 | 99.20 |
| Apr 9, 2025 | 105.35 | 4.16 | 4.11% | 101.19 | 107.34 | 96.99 |
| Apr 8, 2025 | 99.95 | -5.92 | -5.59% | 105.87 | 107.41 | 99.95 |
| Apr 7, 2025 | 105.51 | 2.15 | 2.08% | 103.36 | 108.74 | 101.83 |
| Apr 4, 2025 | 106.27 | -4.97 | -4.47% | 111.24 | 114.24 | 106.27 |
| Apr 3, 2025 | 111.96 | 1.85 | 1.68% | 110.11 | 114.67 | 110.11 |
| Apr 2, 2025 | 110.24 | 0.47 | 0.43% | 109.77 | 113.25 | 109.08 |
| Apr 1, 2025 | 111.30 | -0.01 | -0.01% | 111.31 | 112.81 | 110.27 |
| Mar 31, 2025 | 110.99 | -0.23 | -0.21% | 111.22 | 112.40 | 108.83 |
| Mar 28, 2025 | 111.41 | 0.30 | 0.27% | 111.11 | 112.32 | 109.59 |
| Mar 27, 2025 | 110.95 | 1.96 | 1.80% | 108.99 | 111.70 | 107.95 |
| Mar 26, 2025 | 109.10 | 2.55 | 2.39% | 106.55 | 110.40 | 105.95 |
| Mar 25, 2025 | 107.85 | 1.62 | 1.52% | 106.23 | 107.88 | 104.65 |
| Mar 24, 2025 | 106.36 | -0.71 | -0.66% | 107.07 | 107.64 | 105.95 |
| Mar 21, 2025 | 107.03 | 3.28 | 3.16% | 103.75 | 107.34 | 103.75 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Gilead Company profile
What is Gilead Sciences?
What does the company do?
A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.
A bit of Gilead Sciences’ history
Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.
Who founded Gilead Sciences?
Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.
Current size, team and locations
Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.
Quick facts about Gilead Sciences
- Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
- It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
- In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
- In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.
How to learn the Gilead Sciences share price?
Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the US Tech 100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com